secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096313
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro reports Q2 revenue $25.7M, cash $426M; luvelta trials advancing
---------------------------------------------------------------------

- Revenue $25.7M (up from $10.4M YoY) driven by Astellas collaboration and Vaxcyte agreement.
- Cash, equivalents, and securities $375.6M; Vaxcyte stock fair value $50.4M (total $426M).
- Operating expenses $74.4M (R&D $62.0M, G&A $12.4M); includes non-cash stock comp and depreciation.
- Luvelta Phase 3 REFRαME-O1 randomized portion underway; pediatric AML trial (REFRαME-P1) expected H2 2024.
- Appointed Sukhi Jagpal to Board and Barbara Leyman as Chief Business Development Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024096313/0000950170-24-096313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024096313/stro-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer